Botulinum toxin-A for the treatment of overactive bladder: UK contributions

Journal of Clinical Urology

Volumn 6, Issue 2, 2013, Pages 77-83

  Seth, J H ^a   Dowson, C ^b   Khan, M S ^b   Panicker, J N ^a   Fowler, C J ^a   Dasgupta, P ^b   Sahai, Arun ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Botulinum toxin A; idiopathic detrusor overactivity; neurogenic detrusor overactivity; quality of life; urinary incontinence

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; NEUROTOXIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG SAFETY; FLACCID PARALYSIS; FOLLOW UP; HUMAN; LOCAL ANESTHESIA; META ANALYSIS; MULTIPLE SCLEROSIS; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESIDUAL VOLUME; SPINAL CORD INJURY; SYNAPTIC TRANSMISSION; UNITED KINGDOM; URGE INCONTINENCE; URINARY TRACT INFECTION;

EID: 84880923425     PISSN: 20514158     EISSN: 20514166     Source Type: Journal    
DOI: 10.1177/2051415812473096     Document Type: Article

References (38)

1. NICE. The management of urinary incontinence in women. NICE2006; Clinical Guideline, http://www.nice.org.uk/cg40 (2006, accessed, October).
2. Thuroff JW,Abrams P,Andersson KE, et al.EAU guidelines on urinary incontinence.Eur Urol. 2011;59:387-400.
3. Apostolidis A,Dasgupta P,Denys P, et al.Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: A European consensus report.Eur Urol. 2009;55:100-119.
4. Mangera A,Andersson KE,Apostolidis A, et al.Contemporary management of lower urinary tract disease with botulinum toxin A: A systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).Eur Urol. 2011;60:784-795.
5. Dolly JO,Aoki KR.The structure and mode of action of different botulinum toxins.Eur J Neurol. 2006;13:1-9.
6. Apostolidis A,Dasgupta P,Fowler CJ.Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity.Eur Urol. 2006;49:644-650.
7. Apostolidis A,Popat R,Yiangou Y, et al.Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.J Urol. 2005;174:977-982.
8. Apostolidis A,Jacques TS,Freeman A, et al.Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.Eur Urol. 2008;53:1245-1253.
9. Chuang YC,Huang CC,Kang HY, et al.Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland.J Urol. 2006;175:1158-1163.
10. Chuang YC,Giannantoni A,Chancellor MB.The potential and promise of using botulinum toxin in the prostate gland.BJU Int. 2006;98:28-32.
11. McCloskey KD.Interstitial cells in the urinary bladder - localization and function.Neurourol Urodyn. 2010;29:82-87.
12. Wiseman OJ,Fowler CJ,Landon DN.The role of the human bladder lamina propria myofibroblast.BJU Int. 2003;91:89-93.
13. Roosen A,Datta SN,Chowdhury RA, et al.Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment.Eur Urol. 2009;55:1440-1448.
14. Datta SN,Roosen A,Pullen A, et al.Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.J Urol. 2010;184:2578-2585.
15. Schurch B,Stohrer M,Kramer G, et al.Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results.J Urol. 2000;164:692-697.
16. Mehnert U,Boy S,Schmid M, et al.A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging.World J Urol. 2009;27:397-403.
17. Popat R,Apostolidis A,Kalsi V, et al.A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin.J Urol. 2005;174:984-989.
18. Harper M,Popat RB,Dasgupta R, et al.A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity.BJU Int. 2003;92:325-326.
19. Manecksha RP,Cullen IM,Ahmad S, et al.Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity.Eur Urol. 2012;61:928-935.
20. Kalsi V,Apostolidis A,Popat R, et al.Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.Eur Urol. 2006;49:528-535.
21. Kalsi V,Apostolidis A,Gonzales G, et al.Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.Eur Urol. 2008;54:181-187.
22. Patki PS,Hamid R,Arumugam K, et al.Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.BJU Int. 2006;98:77-82.
23. Hori S,Patki P,Attar KH, et al.Patients' perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury.BJU Int. 2009;104:216-220.
24. Brubaker L,Richter HE,Visco A, et al.Refractory idiopathic urge urinary incontinence and botulinum A injection.J Urol. 2008;180:217-222.
25. Kalsi V,Gonzales G,Popat R, et al.Botulinum injections for the treatment of bladder symptoms of multiple sclerosis.Ann Neurol. 2007;62:452-457.
26. Cruz F,Herschorn S,Aliotta P, et al.Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial.Eur Urol. 2011;60:742-750.
27. Khan S,Panicker J,Roosen A, et al.Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: Patient-reported outcome at 4 weeks.Eur Urol. 2010;57:891-896.
28. Jeffery S,Fynes M,Lee F, et al.Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.BJU Int. 2007;100:1302-1306.
29. Sahai A,Khan MS,Dasgupta P.Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial.J Urol. 2007;177:2231-2236.
30. Khan S,Kessler TM,Apostolidis A, et al.What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.J Urol. 2009;181:1773-1778.
31. Tincello DG,Kenyon S,Abrams KR, et al.Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).Eur Urol. 2012;62:507-514.
32. Sahai A,Khan MS,Le Gall N, et al.Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.Urology. 2008;71:455-459.
33. Sahai A,Sangster P,Kalsi V, et al.Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: Is incomplete bladder emptying predictable?.BJU Int. 2009;103:630-634.
34. Kessler TM,Khan S,Panicker J, et al.Clean intermittent self-catheterization after botulinum neurotoxin type A injections: Short-term effect on quality of life.Obstet Gynecol. 2009;113:1046-1051.
35. Mohee A,Khan A,Harris N, et al.Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).BJU Int.:.
36. Dowson C,Watkins J,Khan MS, et al.Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates.Eur Urol. 2012;61:834-839.
37. Sahai A,Dowson C,Khan MS, et al.Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.Urology. 2010;75:552-558.
38. Kalsi V,Popat RB,Apostolidis A, et al.Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre.Eur Urol. 2006;49:519-527.